Expansion of Liquid Biopsy Test Sites Planned by Merck KGaA, Sysmex | GenomeWeb

NEW YORK (GenomeWeb) – Merck KGaA and Sysmex Inostics are planning to set up additional test sites for the OncoBEAM RAS CRC liquid biopsy diagnostic in Asia and South America.

The two firms began developing the RAS mutation panel following a 2014 deal. The test is based on Sysmex's emulsion-based digital PCR technology, called BEAMing, which stands for beads, emulsions, amplification, and magnetics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.